Toxicity of contrast media: An update

Netherlands Journal of Medicine

Volumn 66, Issue 10, 2008, Pages 416-422

  ten Dam, M A G J ^a   Wetzels, J F M ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Contrast; Gadolinium; Nephropathy

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; IODINATED CONTRAST MEDIUM; SODIUM CHLORIDE;

CONTRAST ENHANCEMENT; DIALYSIS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK ASSESSMENT;

CONTRAST MEDIA; GADOLINIUM; HUMANS; IODINE COMPOUNDS; KIDNEY; KIDNEY FAILURE, ACUTE; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 56849084468     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930-6.
2. Levey EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA. 1996;275:1489-94.
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-75.
4. Van Dijk R, Wetzels JFM, ten Dam MAGJ, et al. Richtlijn 'Voorzorgsmaatregelen bij jodiumhoudende contrastmiddelen'. Ned Tijdschr Geneeskd. 2008;152:742-6.
5. JFM Wetzels. Thorotrast toxicity: the safety of gadolinium compounds. Neth J Med. 2007;65:276-8.
6. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial: the lohexol Cooperative Study. Kidney Int. 1995;47:254-61.
7. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188:171-8.
8. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of iso-osmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692-9.
9. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-9.
10. Bertrand ME, Esplugas E, Piessens J, Rasch W. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: a multicenter, randomized, double blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty VIP Trial Investigators. Circulation. 2000;101:131-6.
11. Hill JA, Cohen MR, Kou WH, et al. Iodixanol a new iso-osmotic nonionic contrast agent compared with iohexol in cardiac angiography. Am J Cardiol. 1994;74:57-63.
12. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol. 1999;72:701-3.
13. Davidson CJ, Laskey WK, Hermiller JB, et al. Randomized trial of contrast media utilization for high-risk PTCA: the COURT trial. Circulation. 2000;101:2172-7.
14. Carraro M, Malalan F, Antonione R, et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol. 1998;8:144-7.
15. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac angiography in renally impaired patients (CARE) study. Circulation. 2007;115:3189-96.
16. Persson PB, Hansell P, Liss P. Pathophysiology of contrast-medium induced nephropathy. Kidney Int. 2005;68:14-22.
17. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93:C29-34.
18. Bader BD, Berger ED, Heede MB et al. What is the best hydration regimen to prevent contrast media-induced nephropathy? Clin Nephrol. 2004;62:1-7.
19. Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003;15:699-702.
20. Mueller C, Buerke G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: a randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;62:329-36.
21. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998;114:1570-4.
22. Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006;21:2120-6.
23. Kelly AM, Dwamena B, Cronin P, Berstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284-94.
24. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-4.
25. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383-8.
26. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89:356-8.
27. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114-8.
28. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289:553-8.
29. MacNeill BD, Harding SA, Bazari H, et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv. 2003;60:458-61.
30. Ochoa A, Pellizzon G, Addala S, et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol. 2004;17:159-65.
31. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773-82.
32. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148:422-9.
33. Azmus AD, Gottschall C, Manica A, et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol. 2005;17:80-4.
34. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328-34.
35. Masuda M, Takahisa Y, Takanao M, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol. 2007;100:787-6.
36. Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007;154:539-44.
37. Recio-Mayoral A, Chaparro M, Prodo B, et al. The Reno-Protective Effect of Hydration With Sodium Bicarbonate Plus N-Acetylcysteine in Patients Undergoing Emergency Percutaneous Coronary Intervention. The RENO Study. J Am Coll Cardiol. 2007;49:1283-88.
38. From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol. 2008;3:10-8.
39. Briguori C, Airoldi F, D'Andrea D, et al. Renal insufficiency following contrast media administration trial (REMEDIAL). A randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211-7.
40. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1.
41. Ting WW, Seabury-Stone M, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903-6.
42. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-62.
43. Grobner T. Gadolinium, a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-8.
44. Cheng S, Abramova L, Saab G, et al. Nephrogenic Fibrosing Dermatopathy associated with exposure to gadolinium containing contrast media in St Louis Missouri, 2002-2006. MMWR. 2007;56:137-41.
45. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast media and nephrogenic systemic fibrosis. Radiology. 2007;242:647-9.
46. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol. 2008;3:DOI 10.2215/CJN.05721207.
47. Cowper SE, Kuo PH, Bucala RB. Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders. Arthritis Rheum. 2007;56:3173-5.
48. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56:3433-41.
49. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-16.
50. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast media? Semin Dialysis. 2008;DOI 10.1111/j.1525-139x.2007.00408.x.